As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Announcement: COVID-19 impact on peer review
The role of DNA methylation in aging has been widely studied. However, epigenetic mutations, here defined as aberrant methylation levels compared to the distribution in a population, are less understood. Our authors investigated longitudinal accumulation of epigenetic mutations, using 994 blood samples collected at up to five time points from 375 individuals in old ages.
Asthma Genetics and Epigenetics
Collection first published: 19 October 2016
Edited by: Lucia Altucci & Marianne Rots
First published: 23 May 2016
Breakthroughs in clinical epigenetics
Edited by: Marianne Rots
First published: 1 March 2015
Graphical Abstracts Now Available
Authors submitting to Clinical Epigenetics now have the option to include a Graphical Abstract when they submit their manuscript. An image may be uploaded during submission which, together with the article title and abstract text, should provide the reader with a visual description of the topic covered in the article. Graphical abstracts will appear in the HTML version of the article (but not in the PDF version). Instructions for including graphical abstracts is available in the Submission Guidelines for the appropriate article types.
3rd Epigenetics and Bioengineering Conference (EpiBio 2019)
September 12-14, 2019 in Barcelona, Spain at the Hotel Barcelona Center
If you'd like to meet or speak with the Editors-in-Chief, both of whom will be attending this meeting, please contact Marianne Rots directly at firstname.lastname@example.org.
Aims & Scope
Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials, translational research, new and innovative methodologies and model organisms providing mechanistic insights. The journal is divided into the following sections:
- Aging and development epigenetics
- Allergy, immunology, and pathogen epigenetics
- Cancer epigenetics and diagnostics
- Cardiovascular epigenetics
- Endocrinology and metabolic epigenetics
- Environmental epigenetics
- Epigenetic biomarkers
- Epigenetic technologies
- Epigenetic therapies and clinical trials
- Innovative therapies
- Lifestyle epigenetics
- Neurology and psychiatry epigenetics
- Regenerative medicine
- Reproductive and transgenerational epigenetics
For more information on the section aims and scope visit our section information page. If you are unclear which section would be best suited to your submission, we invite you to submit a pre-submission inquiry by selecting the Contact Us option here. Please note our new policy regarding submissions involving RNA in our instructions to authors.
Editorial Policy Regarding Submissions Focusing on Non-coding RNAs or RNA Modifications
Differential RNA expression levels (coding or non-coding) or RNA modifications cannot be considered as part of epigenetics, and this includes levels of the RNA modifying enzymes or readers.
The fact that non-coding RNAs might affect other genes at their RNA level classifies these molecules as post-transcriptional gene expression regulators. Although modification of RNAs resembles modifications of DNA or histone proteins, so do post-translational modifications of various proteins. As such, RNAs modifiers as a class of regulators are not different from protein-modifiers, which also are not considered part of epigenetics per se.
For manuscripts on non-coding RNAs to be considered for publication in Clinical Epigenetics, the authors must provide at least one of the following:
- data on the molecular epigenetic regulation of the expression of non-coding RNA (or its modifying enzymes); or
- insights on the mechanism of action of the non-coding RNA on the functioning of the DNA; or
- insights in mitotic stability of the RNA-induced effect.
From the blog
In October 2011, Clinical Epigenetics became a fully open access journal and is now published as part of BioMed Central's portfolio of journals. To view the journal's content prior to this transition, please see SpringerLink.
Annual Journal Metrics
55 days to first decision for reviewed manuscripts only
38 days to first decision for all manuscripts
120 days from submission to acceptance
28 days from acceptance to publication
5.496 - 2-year Impact Factor
5.709 - 5-year Impact Factor
1.175 - Source Normalized Impact per Paper (SNIP)
2.426 - SCImago Journal Rank (SJR)
816 Altmetric mentions